Vascular Graft Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Hemodialysis Access Graft, Endovascular Stent Graft, Peripheral Vascular Graft, Coronary Artery By-pass Graft), By Application (Aneurysms, Kidney Failure, Vascular Occlusion, Coronary Artery Diseases, Other Applications), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 1.41 Billion
CAGR (2026-2031)	7.78%
Fastest Growing Segment	Aneurysms
Largest Market	North America
Market Size (2031)	USD 2.21 Billion

Market Overview

The Global Vascular Graft Market is projected to grow from USD 1.41 Billion in 2025 to USD 2.21 Billion by 2031 at a 7.78% CAGR. Vascular grafts are specialized medical devices, composed of synthetic or biological materials, designed to replace, patch, or redirect blood flow in diseased or damaged vessels. The Global Vascular Graft Market is expanding primarily due to the escalating prevalence of cardiovascular diseases and diabetes, which necessitate critical surgical interventions such as bypass procedures and hemodialysis access. This demand is further amplified by a rapidly aging global population susceptible to arterial obstructions. According to 'International Diabetes Federation', in '2025', approximately 589 million adults were living with diabetes globally, a statistic that underscores the immense burden of chronic conditions driving the requirement for vascular reconstruction.

However, the market faces a significant impediment regarding the long-term biocompatibility and patency of these devices. Post-operative complications, particularly thrombosis, infection, and intimal hyperplasia, remain persistent issues that can lead to graft failure and require costly re-interventions. These adverse biological responses present a substantial barrier to market expansion, especially regarding the adoption of synthetic grafts for small-diameter vessels where failure rates are historically higher compared to autologous options.

Key Market Drivers

The escalating global prevalence of cardiovascular and peripheral vascular diseases is the foremost determinant propelling the demand for vascular grafts. As atherosclerosis and arterial obstructions become more widespread, the necessity for surgical bypass procedures to restore blood flow significantly increases, directly boosting the utility of synthetic and biological grafts. This trend is particularly acute in regions dealing with aging populations and lifestyle-associated risk factors, where vascular reconstruction is often the only viable option to prevent amputation or mortality. According to the American Heart Association, January 2025, in the '2025 Heart Disease and Stroke Statistics Update', cardiovascular disease accounted for approximately 19.41 million global deaths in 2021, a figure that highlights the critical scale of the patient population requiring potential vascular interventions.

Simultaneously, the increasing incidence of End-Stage Renal Disease (ESRD) requiring hemodialysis access acts as a parallel growth catalyst. Vascular grafts, particularly arteriovenous (AV) grafts, are essential for patients who are unsuitable for native fistulas, serving as a vital lifeline for long-term dialysis therapy. This segment is witnessing sustained volume growth as kidney failure rates rise due to comorbidities like diabetes and hypertension. According to the United States Renal Data System, December 2025, in the '2025 Annual Data Report', approximately 131,564 people started treatment for ESRD in the United States in 2023 alone. Reflecting the broader commercial impact of these high-demand clinical areas, According to Terumo Corporation, in 2025, revenue in its Cardiac and Vascular Company segment increased by 12.4% year-on-year, signaling robust market activity driven by these therapeutic needs.

Download Free Sample Report

Key Market Challenges

The major impediment restricting the expansion of the Global Vascular Graft Market is the persistent issue regarding the long-term biocompatibility and patency of synthetic devices. Adverse biological responses, specifically thrombosis, infection, and intimal hyperplasia, frequently result in graft occlusion, necessitating complex and expensive re-interventions. These complications create a substantial economic and clinical burden on healthcare systems, causing surgeons to remain hesitant about adopting synthetic grafts for small-diameter vessels where failure rates are historically elevated. This lack of clinical confidence limits the widespread utilization of off-the-shelf commercial products, thereby reducing the total addressable market for manufacturers.

The impact of this limitation is magnified by the sheer volume of patients requiring durable revascularization who are currently underserved by existing technology. According to 'American Heart Association', in '2025', peripheral artery disease affected more than 200 million people globally, representing a vast demographic critically dependent on successful surgical outcomes. However, the high probability of post-operative failure in synthetic options undermines their viability as a standard of care. Consequently, the market struggles to capitalize on this growing patient base, as the risks associated with graft rejection and mechanical failure directly dampen revenue growth and slow the rate of product penetration.

Key Market Trends

The Adoption of Minimally Invasive Endovascular Aneurysm Repair (EVAR) Techniques is reshaping the competitive landscape, driving a structural transition from open surgical procedures to catheter-based interventions. This trend is fueled by the clinical requirement to minimize operative trauma and reduce recovery times for patients with thoracic and abdominal aortic aneurysms. Manufacturers are prioritizing the development of stent-graft systems with lower profiles and improved flexibility to accommodate complex vascular anatomies, thereby expanding the eligible patient population for these advanced therapies. Validating this sector's expansion, According to Medtronic plc, May 2025, in the 'Fiscal Year 2025 Annual Report', net sales in the Structural Heart & Aortic division increased by 6% year-over-year, a performance driven by the sustained demand for its endovascular product lines.

Concurrently, the Development of Off-the-Shelf Tissue-Engineered Vascular Grafts (TEVGs) is emerging as a solution to the biocompatibility challenges associated with synthetic alternatives. These bioengineered constructs are designed to be universally implantable, eliminating the need for autologous vein harvesting while reducing the risks of infection and rejection inherent in traditional materials. This technology has transitioned from research to commercial application, providing surgeons with immediate access to biological conduits for trauma and vascular repair. Highlighting this commercial progress, According to Humacyte, Inc., November 2025, in the 'Third Quarter 2025 Financial Results', the company reported that sales of Symvess, its acellular tissue-engineered vessel, totaled $703,000 for the quarter, reflecting the initial market penetration of this bio-integrative technology.

Segmental Insights

The aneurysm segment is currently identified as the fastest-growing category in the global vascular graft market. This expansion is primarily driven by the increasing incidence of aortic aneurysms associated with an aging global population and lifestyle factors such as hypertension. Furthermore, improved diagnostic capabilities have led to earlier detection, thereby expanding the patient population eligible for repair procedures. Continuous product clearances by regulatory authorities like the U.S. FDA for endovascular stent grafts have also improved treatment accessibility. Consequently, the demand for these grafts remains strong as healthcare systems address the rising burden of vascular diseases.

Regional Insights

North America maintains a leading position in the global vascular graft market, driven by the high incidence of cardiovascular disorders and diabetes across the region. This market dominance is sustained by a robust healthcare infrastructure that supports the widespread adoption of surgical interventions. Additionally, favorable reimbursement policies managed by institutions like the Centers for Medicare & Medicaid Services enable broader patient access to essential vascular procedures. The structured product approval processes maintained by the U.S. Food and Drug Administration further ensure the availability of verified medical devices, solidifying the region's strong market standing.

Recent Developments

• In October 2025, Terumo Aortic entered into a strategic collaboration with Bentley, a global manufacturer of covered stents, to conduct a pivotal clinical study in the United States. The partnership aims to gather data to support an Investigational Device Exemption (IDE) from the FDA for the use of Terumo Aortic’s Fenestrated TREO Abdominal Stent-Graft System in conjunction with Bentley’s BeFlared bridging stent. This study is intended to validate the combined solution for the treatment of complex juxtarenal and suprarenal abdominal aortic aneurysms. The collaboration seeks to provide physicians with an integrated, patient-specific endovascular solution that ensures perfusion to vital organs through reliable bridging stents, ultimately expanding treatment options for patients with complex aortic anatomies in the U.S. market.
• In December 2024, Humacyte, Inc. secured full approval from the U.S. Food and Drug Administration (FDA) for SYMVESS, its acellular tissue engineered vessel. This bioengineered product is indicated for use as a vascular conduit in adult patients suffering from extremity arterial injury who require urgent revascularization and lack suitable autologous vein grafts. The approval was based on clinical data showing favorable rates of patency and limb salvage compared to synthetic benchmarks. This development represents the first FDA-approved product from the company’s proprietary platform, offering an off-the-shelf human tissue alternative that resists infection and remodels into the patient’s native tissue over time, addressing a critical need in vascular trauma management.
• In November 2024, Endologix LLC released the final 36-month results from its DETOUR2 clinical trial, which evaluated the safety and effectiveness of the DETOUR System for treating complex peripheral arterial disease. Presented at a major medical conference, the data demonstrated that the system, which utilizes TORUS stent grafts to create a percutaneous transmural arterial bypass, achieved durable efficacy comparable to traditional open surgical bypass with synthetic grafts. The study highlighted a low rate of complications and deep venous thrombosis, reinforcing the potential of this minimally invasive approach. The company’s leadership noted that these long-term findings validate the system as a viable alternative for patients with long-segment superficial femoral artery disease who require revascularization.
• In January 2024, W. L. Gore & Associates announced that it had received approval from the U.S. Food and Drug Administration (FDA) for a lower profile configuration of its GORE VIABAHN VBX Balloon Expandable Endoprosthesis. This regulatory clearance marked a significant expansion of the company’s vascular graft portfolio, as the device is designed to treat de novo or restenotic lesions in iliac arteries, including those at the aortic bifurcation. The new design allows for compatibility with 6 Fr sheaths for the majority of sizes, thereby reducing the risk of access complications and enabling physicians to treat complex vascular diseases with greater precision. The update reflects the company's focus on improving endovascular solutions for patients with challenging anatomical requirements.

Key Market Players

• Abbott Laboratories
• Braun Melsungen AG
• Bard Peripheral Vascular Inc.
• Cordis Corporation
• Cook Medical LLC
• Endologix Inc.
• Getinge Group
• LeMaitre Vascular Inc.
• Medtronic PLC
• Terumo Medical Corporation.

By Product	By Application	By Region
Hemodialysis Access Graft Endovascular Stent Graft Peripheral Vascular Graft Coronary Artery	Aneurysms Kidney Failure Vascular Occlusion Coronary Artery Diseases Other Applications	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Vascular Graft Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Vascular Graft Market, By Product:

• Hemodialysis Access Graft
• Endovascular Stent Graft
• Peripheral Vascular Graft
• Coronary Artery

• Vascular Graft Market, By Application:

• Aneurysms
• Kidney Failure
• Vascular Occlusion
• Coronary Artery Diseases
• Other Applications

• Vascular Graft Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE